{
  "id": "606b79da94d57fd87900006e",
  "type": "summary",
  "question": "What has capmatinib received FDA approval for in 2020?",
  "ideal_answer": "In May 2020, oral capmatinib received its first global approval in the USA for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32557339"
  ],
  "snippets": [
    {
      "text": " In May 2020, oral capmatinib received its first global approval in the USA for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557339",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}